At the news
? BULLISHIMPACT 6/10 8-K filed Apr 24, 2026 at 16:05 ET
PDS Biotechnology updated its corporate presentation deck, which includes positive clinical trial data for its lead compound PDS0101 in combination with pembrolizumab for HPV16-positive recurrent/metastatic head and neck cancer. The presentation highlights a median overall survival of 39.3 months and a 77.4% disease control rate, which is significantly better than the 12-18 month benchmark with current standard of care.
- PDS Biotechnology updated its corporate presentation deck on April 24, 2026
- The presentation highlights clinical data for PDS0101 in combination with pembrolizumab for HPV16-positive recurrent/metastatic head and neck cancer
- The trial showed a median overall survival of 39.3 months, compared to a 12-18 month benchmark with current standard of care
- The disease control rate was 77.4%
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access